Effects of the Carnitine-acyltransferase Inhibitor Etomoxir on Insulin Sensitivity, Energy Expenditure and Substrate Oxidation in NIDDM
The DOI matches its Crossref record.
Abstract
We studied the influence of Etomoxir on fat and carbohydrate oxidation, and the influence of these changes on insulin sensitivity in type 2 diabetic patients. Etomoxir is an oxirane carboxylic acid derivative that specifically inactivates carnitine-acyltransferase I (CAT I, EC: 2.3.1.21), the key enzyme for the transport of long-chain acyl-CoA compounds into the mitochondria. Thus, oxidation of fatty acids should be reduced by this drug and glucose utilisation be increased according to the Randle mechanism. In order to test this hypothesis, we measured oxidative and non-oxidative glucose utilisation using the euglycaemic hyperinsulinaemic clamp technique, the isotope dilution mass spectrometry (IDMS) method with stable isotopes (6,6-D2-glucose) and indirect calorimetry. The clamps lasted 5 hours, indirect calorimetry was performed during the last hour and calculations of glucose disposal were based on steady state conditions during the last 30 minutes. Twelve type 2 diabetic patients were treated with 100 mg etomoxir/per day for 3 days in this placebo-controlled, randomized, double-blind study. Treatment resulted in a significant increase in carbohydrate oxidation (from 72 to 113 g/24 h, p = 0.039), decrease in fat oxidation (from 139 to 114 g/24 h, p = 0.037), and decrease of the glucose appearance rate (RA) in the basal state (from 1.85 to 1.70 mg/kg min., p = 0.014). During the euglycaemic clamp neither RA (3.30 and 3.20 mg/kg min., p = 0.471) nor the glucose infusion rate (4.28 and 4.53 mg/kg min., p = 0.125) showed significant changes. In addition, no significant changes in glucose and fat oxidation were detected during the hyperinsulinaemic clamp. Under basal conditions non-oxidative glucose utilisation was decreased by etomoxir (1.26 and 0.80 mg/ kg x min). Thus, we could demonstrate a decrease in fat and increase in glucose oxidation by etomoxir, but non-oxidative glucose utilisation was decreased. No significant changes could be demonstrated under clamp conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, when insulin sensitivity was assessed by the euglycemic clamp technique, some studies reported improvements after etomoxir treatment whereas others found the opposite effect (Dobbins et al., 2001; Hubinger et al., 1997).”
From Lipid-Induced Mitochondrial Stress and Insulin Action in Muscle (2012) · cites this paper as Hubinger et al., 1997
Citations
Cites
Still being checked.
Cited by
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 377
Lipid-Induced Mitochondrial Stress and Insulin Action in Muscle
Muoio, D. M., & Neufer, P. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.010 · Cited by 343
Dobbins, R. L., Szczepaniak, L. S., Bentley, B., Esser, V., Myhill, J., & McGarry, J. D. (2001) · Diabetes · doi:10.2337/diabetes.50.1.123 · Cited by 315
Tuning fatty acid oxidation in skeletal muscle with dietary fat and exercise
Fritzen, A. M., Lundsgaard, A.-M., & Kiens, B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0405-1 · Cited by 180
Murray, A. J., Panagia, M., Hauton, D., Gibbons, G. F., & Clarke, K. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3496 · Cited by 134
Impaired mitochondrial fat oxidation induces adaptive remodeling of muscle metabolism
Wicks, S. E., Vandanmagsar, B., Haynie, K. R., Fuller, S. E., Warfel, J. D., Stephens, J. M., Wang, M., Han, X., Zhang, J., Noland, R. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418560112 · Cited by 131
Energy expenditure, sex, and endogenous fuel availability in humans
Nielsen, S., Guo, Z., Albu, J. B., Klein, S., O’Brien, P. C., & Jensen, M. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16253 · Cited by 129
Keung, W., Ussher, J. R., Jaswal, J. S., Raubenheimer, M., Lam, V. H. M., Wagg, C. S., & Lopaschuk, G. D. (2013) · Diabetes · doi:10.2337/db12-0259 · Cited by 128
Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells Proliferation
Tirado-Vélez, J. M., Joumady, I., Sáez-Benito, A., Cózar‐Castellano, I., & Perdomo, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046484 · Cited by 115
Ceccarelli, S. M., Chomienne, O., Gubler, M., & Arduini, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100809g · Cited by 119
Coort, S. L., Bonen, A., Vusse, G. J., Glatz, J. F. C., & Luiken, J. J. F. P. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-9030-5 · Cited by 114
Conti, R., Mannucci, E., Pessotto, P., Tassoni, E., Carminati, P., Giannessi, F., & Arduini, A. (2011) · Diabetes · doi:10.2337/db10-0346 · Cited by 98
Timmers, S., Nabben, M., Bosma, M., van Bree, B., Lenaers, E., van Beurden, D., Schaart, G., Westerterp-Plantenga, M. S., Langhans, W., Hesselink, M. K. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206868109 · Cited by 80
“For example, inhibitors of carnitine palmitoyl transferase 1 (CPT1) like ethyl-2-[6-(4-chlorophenoxy) hexyl]-oxirane-2-carboxylate (etomoxir) have initially been shown to effectively lower blood glucose levels in diabetic patients (6, 7).”
BackgroundMolecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene CPT1C to Promote Survival
Reilly, P. T., & Mak, T. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3281 · Cited by 72
Hepatic ATGL knockdown uncouples glucose intolerance from liver TAG accumulation
Ong, K. T., Mashek, M. T., Bu, S. Y., & Mashek, D. G. (2012) · The FASEB Journal · doi:10.1096/fj.12-213454 · Cited by 54
Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target
Rupp, H., & Zarain‐Herzberg, Á. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.3.345 · Cited by 44
Estañ, M. C., Calviño, E., Calvo, S., Guillén-Guío, B., Boyano-Adánez, M. D. C., de Blas, E., Rial, E., & Aller, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115250 · Cited by 42
Carnitine Palmitoyltransferase 1b Deficiency Protects Mice from Diet-Induced Insulin Resistance
Yang, Q. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000361 · Cited by 48
Griesel, B. A., Weems, J. C., Russell, R. A., Abel, E. D., Humphries, K. M., & Olson, A. L. (2010) · Diabetes · doi:10.2337/db09-1542 · Cited by 39
Högberg, H. T., Engblom, L. O. M., Ekdahl, Å., Lidell, V., Walum, E., & Alberts, P. (2006) · Obesity · doi:10.1038/oby.2006.76 · Cited by 39
Recent Developments and Emerging Therapies for Type 2 Diabetes Mellitus
Evans, A. J., & Krentz, A. J. (1999) · Drugs in R&D · doi:10.2165/00126839-199902020-00001 · Cited by 36
Glucometabolic consequences of acute and prolonged inhibition of fatty acid oxidation
Lundsgaard, A., Fritzen, A. M., Nicolaisen, T. S., Carl, C. S., Sjøberg, K. A., Raun, S. H., Klein, A. B., Sanchez-Quant, E., Langer, J., Ørskov, C., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.ra119000177 · Cited by 36
Acute effects of pharmacological modifications of fatty acid metabolism on human satiety
Gatta‐Cherifi, B., Zuberbuehler, C. A., Arnold, M., Aubert, R., Langhans, W., & Chapelot, D. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114508143604 · Cited by 32
Totzke, U., Hübinger, A., & Bairlein, F. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1580191 · Cited by 25
Self-citationGhosh, S., Wicks, S. E., Vandanmagsar, B., Mendoza, T. M., Bayless, D. S., Salbaum, J. M., Dearth, S. P., Campagna, S. R., Mynatt, R. L., & Noland, R. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006074 · Cited by 28
The effect of etomoxir on 24-h substrate oxidation and satiety in humans,,
Schrauwen‐Hinderling, V. B., Schrauwen, P., Langhans, W., & Westerterp‐Plantenga, M. S. (2002) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.1.141 · Cited by 22
Serup, A. K., Alsted, T. J., Jordy, A. B., Schjerling, P., Holm, C., & Kiens, B. (2016) · Diabetes · doi:10.2337/db16-0655 · Cited by 23
Musutova, M., Elkalaf, M., Klubíčková, N., Koc, M., Povysil, S., Rambousek, J., Volckaert, B., Duška, F., Trinh, M. D., Kalous, M., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00616 · Cited by 20
Differential effects of etomoxir treatment on cardiac Na+-K+ ATPase subunits in diabetic rats
Kato, K., Lukas, A., Chapman, D. C., Rupp, H., & Dhalla, N. S. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1014841216418 · Cited by 17
Rizzo, A., Angioni, S. L., Spedicato, M., Minoia, G., Mutinati, M., Trisolini, C., & Sciorsci, R. L. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.507293 · Cited by 15
Recent advances in understanding glucose transport and glucose disposal
Olson, A. L., & Humphries, K. M. (2020) · F1000Research · doi:10.12688/f1000research.22237.1 · Cited by 12
Jacobson, J. D., Midyett, L. K., Garg, U., Sherman, A., & Patel, C. B. (2011) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000144 · Cited by 10
Are Individuals With Type 2 Diabetes Metabolically Inflexible? A Systematic Review and Meta‐Analysis
Hansen, M., Lange, K. K., Stausholm, M. B., & Dela, F. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70044 · Cited by 10
Oral Antidiabetic Drugs in Research and Development
Bischoff, H., & Lebovitz, H. E. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-09127-2_23 · Cited by 4
Stoyanova, S., & Bogdanov, M. G. (2025) · Molecules · doi:10.3390/molecules30030735 · Cited by 4
Ong, K. T. (2013) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 2
Koudelková, K., Moro, C., & Gojda, J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70068 · Cited by 1
Metadata
- Authors
- Hübinger, A., Knode, O., Susanto, F., Reinauer, H., & Gries, F.
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 1997-09
- Volume
- 29
- Issue
- 09
- Pages
- 436-439
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W1995483958
- Cited by
- 38
- References
- 0
- Citations by year
- 2025: 3 · 2020: 2 · 2019: 3 · 2018: 1 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 6
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hormone and Metabolic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- etomoxir, type 2 diabetes, insulin sensitivity, glucose oxidation, fat oxidation, substrate oxidation, Randle cycle, energy expenditure, glucose appearance rate, hyperinsulinemic-euglycemic clamp, euglycaemic clamp, isotope dilution mass spectrometry
- MeSH terms
- Adult, Aged, Blood Glucose, Carnitine O-Acetyltransferase, Diabetes Mellitus, Type 2, Double-Blind Method, Energy Metabolism, Enzyme Inhibitors, Female, Humans, Insulin, Insulin Resistance, Kinetics, Male, Middle Aged, Oxidation-Reduction, Placebos, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.